Physician profile
Paul Zerbinopoulos
NPI 1154375418
$8,813.61
in general payments reported to CMS, 2019-2025
23 companies · $2,028 in 2025
The $2,028 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,724 · 2020: $937 · 2021: $448 · 2022: $444 · 2023: $1,028 · 2024: $1,205 · 2025: $2,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,244 · Travel and Lodging: $12.00 · Education: $4.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,244.04 |
| Travel and Lodging | $12.00 |
| Education | $4.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $3,168.96 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $893.83 | 2022-2025 | Miebo, Xiidra, Infuse |
| Alcon Vision LLC | $781.76 | 2022-2025 | Eysuvis, Rhopressa, Rocklatan |
| Glaukos Corporation | $671.40 | 2024-2025 | Radius, Ce-Marked Kxla System, Idosetr |
| Johnson & Johnson Vision Care, INC. | $586.42 | 2019-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $412.49 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $400.12 | 2022-2025 | Tyrvaya, Ryzumvi |
| Coopervision INC. | $354.73 | 2019-2025 | Myday Contact Lens |
| Aerie Pharmaceuticals, INC. | $247.85 | 2019-2021 | |
| Dompe US, INC. | $226.94 | 2025 | Oxervate |
| Visionary Optics LLC | $179.85 | 2023 | |
| Biotissue Holdings INC. | $162.75 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $156.48 | 2021 | |
| Allergan, INC. | $154.10 | 2019-2022 | |
| Sight Sciences, INC. | $147.49 | 2025 | Tearcare System |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $94.03 | 2022-2025 | Durysta |
| Akorn Operating Company LLC | $34.24 | 2021 | |
| Shire North American Group INC | $32.41 | 2019 | |
| Kala Pharmaceuticals, INC. | $28.77 | 2021 | |
| Rxsight INC | $23.87 | 2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Sun Pharmaceutical Industries INC. | $23.78 | 2025 | |
| Eyevance Pharmaceuticals LLC | $16.32 | 2022 | |
| Abb Con-Cise Optical Group LLC | $15.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Zerbinopoulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.